Madrigal Pharmaceuticals (MDGL) Q4 2023: Loss Narrows, Revenue Surges 210%

Madrigal Pharmaceuticals, Inc. (MDGL) reported a loss for the fourth quarter of 2024, though revenue significantly increased compared to the same period last year. The company’s financial results, released on February 26, 2025, reflect ongoing investment in its key therapeutic, Rezdiffra, for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), formerly known as NASH.

The company’s bottom line for the quarter totaled a loss of $58.58 million, or $2.57 per share. This represents an improvement compared to the loss of $59.42 million, or $2.71 per share, reported in the fourth quarter of 2023. Despite the continued loss, the results surpassed analyst expectations. According to a report from Yahoo Finance, the average estimate of eight analysts surveyed by Zacks Investment Research was for a loss of $4.12 per share.

A substantial driver of the financial results was a 210.8% increase in revenue, rising to $321.08 million from $103.32 million in the same quarter of the previous year. This surge in revenue is directly attributable to the launch and increasing uptake of Rezdiffra, which received FDA approval in January 2024 and is designed to reduce liver fat in adults with MASH.

Understanding MASH and Rezdiffra

MASH is a serious liver condition characterized by inflammation and damage caused by a buildup of fat in the liver. It can progress to cirrhosis, liver failure, and the need for liver transplantation. Previously known as nonalcoholic steatohepatitis (NASH), the name change to MASH reflects a growing understanding of the disease’s complex metabolic origins. It’s increasingly recognized as a significant public health concern, particularly with the rising rates of obesity and type 2 diabetes.

Rezdiffra (selumetinib) is a selective inhibitor of the MEK enzyme, a key component of a signaling pathway involved in inflammation and fibrosis. Clinical trials have demonstrated that Rezdiffra can significantly reduce liver fat and improve liver health in patients with MASH. The drug’s approval marked a major milestone in the treatment of this previously underserved condition.

Full Year 2024 Performance

For the full year 2024, Madrigal Pharmaceuticals reported a loss of $465.9 million, or $21.90 per share. Total revenue for the year reached $180.1 million. The company highlighted key business achievements in its year-end report, focusing on the successful launch of Rezdiffra and ongoing efforts to expand access to the medication.

Market Reaction and Future Outlook

Despite the positive revenue figures, Madrigal’s stock experienced a decline in premarket trading on Thursday, February 19, 2026, dropping approximately 8% following the release of the Q4 2025 financial report. This reaction, as reported by Seeking Alpha, appears to be driven by the larger-than-expected loss for the quarter.

The company’s financial performance reflects the substantial investment required to commercialize a new drug, including manufacturing, marketing, and sales infrastructure. While Rezdiffra is generating significant revenue, these costs are currently outweighing the income.

Looking ahead, Madrigal Pharmaceuticals is focused on continuing to drive Rezdiffra adoption, expanding its clinical development pipeline, and exploring potential new indications for its therapies. The company’s success will depend on its ability to effectively navigate the evolving MASH treatment landscape and demonstrate the long-term clinical and economic value of Rezdiffra.

The financial results indicate a company in a transitional phase, moving from a research and development focus to a commercial-stage biopharmaceutical company. The substantial revenue growth demonstrates the potential of Rezdiffra, but continued investment and careful financial management will be crucial for achieving profitability and sustained growth.